What is INmune Bio Inc. (INMB) stock price today?

INmune Bio Inc. (INMB) is currently trading at $1.89, up 3.28% today.

What is INMB P/E ratio?

INmune Bio Inc.'s P/E ratio is -2.81. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is INMB return on equity (ROE)?

INmune Bio Inc.'s return on equity (ROE) is -82.87%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is INmune Bio Inc.'s market cap?

INmune Bio Inc. has a market capitalization of $50.25M.

NASDAQ · Biotechnology

INmune Bio Inc. (INMB) Stock

$1.89 +3.28% NASDAQ: INMB Healthcare

Valuation

Metric	Value
Price	$1.89
Market Cap	$50.25M
P/E Ratio	-2.81
P/B Ratio	2.55
P/S Ratio	776.29
EPS (TTM)	$-0.53
52-Week High	$2.60
52-Week Low	$1.09
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-82.87%
ROA	-68.60%
ROCE	-96.37%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.07
Current Ratio	3.75

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-29.0M	$-26.0M	$-30.0M	$-43.0M	$-31.0M
Net Profit	$-30.0M	$-27.0M	$-30.0M	$-42.0M	$-46.0M
EPS	$-1.88	$-1.52	$-1.67	$-2.11	$-1.86
Op Margin	-16106.6%	-6938.8%	-19187.7%	-304535.7%	-61738.0%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$100.0M	$82.0M	$57.0M	$40.0M	$32.0M
Total Liabilities	$20.0M	$22.0M	$19.0M	$7.0M	$9.0M
Cash	$75.0M	$52.0M	$36.0M	$21.0M	$25.0M
Borrowings	$15.0M	$15.0M	$10.0M	$0	$1.0M

Latest News

INmune Bio Says Study Shows Drug Candidate Reduced Alzheimer's-Related Brain Changes After Brain Injury MT Newswires · Jul 15, 2026 INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study GlobeNewswire · Jul 15, 2026 INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC GlobeNewswire · Jul 9, 2026 Sector Update: Healthcare Stocks Edge Higher Premarket Wednesday MT Newswires · Jul 1, 2026 INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion GlobeNewswire · Jul 1, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-29.0M	$-23.0M	$-12.0M	$-33.0M	$-23.0M
Investing Cash Flow	$-30.0M	$0	$0	$0	$-2.0M
Financing Cash Flow	$1.0M	$0	$0	$0	$0
Net Cash Flow	$53.0M	$-23.0M	$-16.0M	$-15.0M	$4.0M
Free Cash Flow	$-44.0M	$-23.0M	$-12.0M	$-33.0M	$-24.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.02
EV / EBITDA	-1.90
FCF Yield	-31.61%
Quick Ratio	4.04
Interest Coverage	0.00
Return 1Y	3.86%
Return 3Y	-80.28%
Return 5Y	-89.82%

Ownership

Insiders Held11.23%

Institutions Held19.68%

Institutions Float Held22.17%

Institutional Holder	Shares	Report Date
Blackrock Inc.	1,194,112	2026-03-31
Vanguard Capital Management LLC	687,015	2026-03-31
Geode Capital Management, LLC	494,969	2026-03-31
State Street Corporation	290,879	2026-03-31
AQR Capital Management, LLC	270,317	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALGSAligos Therapeutics, Inc.	$5.34	+0.56%	-0.76	$33.05M	0.00%
BRNSBarinthus Biotherapeutics plc	$0.67	+4.69%	-0.41	—	0.00%
CVMCel-Sci Corporation	$1.94	-0.51%	-0.90	$13.33M	0.00%
FGENFibroGen, Inc.	$9.07	-1.63%	0.22	$36.69M	0.00%
MRSNMersana Therapeutics, Inc.	$29.08	+0.00%	-2.59	$145.36M	0.00%

About INmune Bio Inc.

INmune Bio Inc. is led by CEO David J. Moss, publicly traded since 2019.

INmune Bio Inc. (INMB) stock trades at $1.89 with a market capitalization of $50.25M. The stock is valued at a price-to-earnings (P/E) ratio of -2.81, price-to-book of 2.55, price-to-sales of 776.29. Over the past 52 weeks the stock has ranged between $1.09 and $2.60, and currently trades 27.3% below its 52-week high.

On profitability, INmune Bio Inc. generates a return on equity (ROE) of -82.87%, return on capital employed of -96.37%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides